Shares of Doximity (NYSE: DOCS) dipped more than 10% the morning after it reported results from its fiscal third quarter that ended on Dec. 31, 2022. The company revised its forward-looking guidance downward, and the market made a knee-jerk reaction.

Nobody likes to hear the companies they've invested in say they were too optimistic about the future. Luckily, Doximity had plenty of encouraging news to share as well. Just read on to see why this stock is a smart buy right now despite its guidance revision.

The company outperformed Wall Street's expectations during its fiscal third quarter, but management also told investors it would miss the fiscal 2023 revenue estimate it shared just a few months ago.

Continue reading

Source Fool.com